BOULDER, Colo., April 30, 2018 /PRNewswire/ -- Array BioPharma
Inc. (Nasdaq: ARRY) will report financial results for the
third quarter of fiscal 2018 and hold a conference call to discuss
those results on Wednesday, May 9,
2018. Ron Squarer, Chief Executive Officer, will lead the
call.
|
Date:
|
Wednesday, May 9,
2018
|
|
Time:
|
9:00 a.m. Eastern
Time
|
|
Toll-Free:
|
(844)
464-3927
|
|
Toll:
|
(765)
507-2598
|
|
Pass
Code:
|
6465079
|
Webcast, including Replay and Conference Call Slides:
https://edge.media-server.com/m6/p/s5fgkv2a
About Array BioPharma
Array BioPharma Inc. is a
biopharmaceutical company focused on the discovery, development and
commercialization of targeted small molecule drugs to treat
patients afflicted with cancer and other conditions. Ten
registration studies are currently advancing related to eight
Array-owned or partnered drugs: encorafenib (LGX818), binimetinib
(MEK162), ARRY-797, selumetinib (partnered with AstraZeneca),
danoprevir (partnered with Roche), ipatasertib (partnered with
Genentech), larotrectinib (partnered with Loxo Oncology) and
tucatinib (partnered with Seattle Genetics). For more information
on Array, please go to www.arraybiopharma.com.
CONTACT:
Array BioPharma
Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate
Communications
(303) 381-6600
ir@arraybiopharma.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-third-quarter-of-fiscal-2018-on-may-9-2018-300639125.html
SOURCE Array BioPharma Inc.